Hepatitis B Virus Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Test Type (Hepatitis B Surface Antigen Test (HBsAg), Anti-hepatitis B Surface Antibody Test, Hepatitis B Core Antigen Test (HBcAb), Anti-hepatitis B Core Antibody Test, HBV DNA Test, and Others), By Techniques (PCR, Radioimmunoassay (RIA), Enzyme-linked immunosorbent assay (ELISA) and Others), By End User (Hospitals, Diagnostic Centers and Clinics) and Region Forecast 2020-2031

Hepatitis B virus testing market size was valued at US$ 1,010.8 million in 2024 and is expected to reach US$ 1,570.7 million by 2031, growing at a significant CAGR of 6.5% from 2025-2031. Increase in liver cancer cases, growing aging population, healthcare spending, and urbanization. leading to better monitoring and screening procedures. In addition, government initiatives to grow awareness in public, increase in R&D spending by companies, and growing demand for biomarker tests due to their accuracy are expected to boost the market during the forecast period.

However, factors such as lack of awareness in developing countries, stringent regulatory rules, rigid competition, and high cost of testing are expected to hamper the market over the forecast period. Hepatitis B is a liver disease caused by the Hepatitis B virus (HBV). Hepatitis B viral infection control ranges can form mild infection which lasts a few weeks and a chronic infection that may lead to liver disorders and even death. Hepatitis B is one of the global health problems. Hepatitis B can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The virus is transmitted through contact with the blood or other body fluids of an infected person.

According to the World Health Organization, 257 million people are living with hepatitis B virus infection worldwide, and in 2015, 887,000 hepatitis B resulted in deaths. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market. In addition, The global market report includes human demographics; regulatory scenario, and competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the global market to better equip clients with possible investment opportunities across the regions (regional Investment hot spots) and market unmet needs (Product opportunities).

Key Developments:

• On Feb 2019: Abbott said it received the CE Mark for its world's most sensitive test of the rapid diagnostic, which tests for hepatitis B surface antigen in serum, plasma, or whole blood. The Determine™ HBsAg 2 test was an easy-to-use, rapid lateral flow test that enabled the identification of those infected and facilitated linkage to care for all healthcare settings.